Vivera is an innovative, science-driven pharmaceutical company focused on researching, developing, and improving patient-centric novel therapies and medical device technologies for various indications. At the onset of 2019, Vivera’s core business centered around its pharmaceuticals and medical device divisions, laying a roadmap for our future. Today, we have four divisions, including technologies, biosciences medical devices, and advanced diagnostics, each working synergistically to support Vivera’s core mission of putting patients first.
The Company’s Medical Technologies division brings innovative solutions to enhance patient-provider interactions, improve medication safety and compliance, and enable more effective communication throughout the healthcare supply chain and among relevant parties. Within this division, the Company holds patents on ZICOH, a high-tech, intelligent, dose-controlled medical device. It has also received a patent for its portable telemedicine station, MDZone.
Within its biosciences division, Vivera has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use. One focus is on utilizing TABMELT technology to expand therapies for various psychiatric and neurological conditions. The Company recently executed a Letter of Intent (LOI) to enter a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), an Institute within the National Institutes of Health (NIH) that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. The collaboration aims to identify therapeutic agents for the potential treatment of stuttering disorders, estimated to affect approximately 70 million people worldwide.
From day one, Vivera’s mission has been to support the needs of our most underserved communities, finding new and innovative ways to support patients and medical providers. From the opioid crisis to mental health and beyond, the Company strives to fulfill its purpose and promise toward patient-centric research and development that puts the total health of the patient front and center.